Contrast performance best with zero spherical aberrations

Article

By using adaptive optics and physiological eye models, Pablo Artal and colleagues from Universidad de Murcia, Spain have determined that contrast performance peaks when spherical aberration is completely corrected.

By using adaptive optics and physiological eye models, Pablo Artal and colleagues from Universidad de Murcia, Spain have determined that contrast performance peaks when spherical aberration is completely corrected.

An adaptive-optics based vision simulator that allowed for simultaneous manipulation of ocular wavefront aberration and measurement of visual performance was created. The simulator consisted of a wavefront sensor, an adaptive optics mirror and a visual testing path. Subjective measurements of contrast sensitivity in five subjects with different levels of naturally occurring spherical aberration, at 15 c/deg with a 4.8 mm pupil, were performed.

Contrast sensitivity was measured for spherical aberration values of -0.09, 0.0, 0.09 and 0.182 µm with the other naturally occurring aberrations of the eye present and corrected and with defocus varying from +0.5 to -0.5 D. The same levels of spherical aberration were compared in physiological eye models to establish tolerances to tilt and decentration and to verify through-focus performance.

Each subject experienced peak contrast sensitivity performance with varying levels of spherical aberration when their natural aberrations were present, however, the average contrast performance peaked with 0 µm of spherical aberration.

The researchers concluded that contrast performance is at its best when spherical aberration is completely corrected.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.